Krka is one of the leading generic pharmaceutical companies with 70 years of experience. Today, the high quality of our products is recognised all over the world. Our achievements have been built by generations of Krka employees through their courageous and visionary outlook.
Our attitude to people, the environment and the natural heritage as well as our strategic business direction all contribute to a better quality of life.
Operating figures are dynamic. The latest operating figures are published in the latest Annual Report.
2023 Krka Group Performance Estimate
The Management Board of Krka, d. d. held a press conference today presenting the Krka Group 2023 preliminary unaudited performance results, which the Krka Supervisory Board had discussed at its meeting yesterday. The Krka Group generated €1,806.4 million of revenue last year, up €88.9 million, or 5%, compared to 2022.
Establishment of a joint venture in India
Krka and Laurus Labs Ltd. from India have reached an agreement to establish a joint venture company Krka Pharma Pvt. Ltd. in Hyderabad, India. Krka will hold 51% and Laurus 49% share in the joint venture. The registered capital of the newly founded company amounts to up to 50 million euros in Indian rupees. The joint venture will enable the production of finished products for the new markets, including the Indian market.
Excellence is not an act, but a habit
In this year’s Slovenian Business Excellence survey, conducted by an independent external agency for the fifth year in a row, Krka once again scored highly across key parameters, winning the top place among 54 surveyed companies according to both the business community and the general public, and thus maintaining its leading position among Slovenian companies.
In our commitment to healthy living we offer a broad range of high-quality prescription pharmaceuticals, non-prescription products and animal health products.